NCT04564235

Brief Summary

  1. 1.Inclusion of 5 families Inclusions will be made by the clinical genetics department of the Rouen University Hospital (monocentric study) and will correspond to trios of parents + child with unexplained developmental abnormalities. The inclusion of patients will be integrated in routine care and will have as immediate benefit for the included families the extensive analysis of the proband and their parents' genomes by short and long read sequencing techniques, which represent the most comprehensive diagnostic tests for developmental diseases, and which are not currently routinely available. Inclusion in clinical genetics by clinicians accustomed to prescribing genome-wide analyses will allow clear and complete information to families. Collection of consents. The trio's DNA will already be available at the molecular genetics laboratory, and a new blood sample may be proposed if necessary. Collection of sperm from the father.
  2. 2.Identification of a large set of de novo mutations. Extraction of blood DNA and sending for sequencing of the complete genome to the National Centre for Research in Human Genomics (CNRGH, Evry), in the framework of a collaboration already initiated. Analysis of the sequencing data thanks to the already existing expertise in Rouen. Identification of about 40-120 de novo mutations per trio. At this stage: interpretation of the variations identified with the secondary objective of identifying the cause of the disease in children. Long read genomes will allow to phase the de novo variants to the paternal or to the maternal haplotype.
  3. 3.Search for de novo mutations in paternal sperm samples. Extraction of spermatic DNA. Design of a sequencing panel targeting the genetic variations identified in the different trios. Preparation of the libraries, targeted high throughput sequencing at great depth thanks to the techniques and equipment already operational. Specific search for the de novo variations identified in the probands (in 2.), with for each evaluation of (i) the presence of the variation in the sperm sample, (ii) the quantity of mosaicism, reflecting the proportion of carrier spermatozoa and therefore the risk of recurrence, (iii) the presence of my variation in the blood sample of both parents in deep sequencing.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Feb 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 21, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 25, 2020

Completed
5 months until next milestone

Study Start

First participant enrolled

February 24, 2021

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 12, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 12, 2022

Completed
Last Updated

April 20, 2026

Status Verified

February 1, 2026

Enrollment Period

1.8 years

First QC Date

September 21, 2020

Last Update Submit

April 16, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Proportion of the patient's de novo mutations detectable in the father's sperm

    Day 1

Secondary Outcomes (1)

  • Number of patients for whom molecular diagnosis has been obtained (cause of developmental disability identified) ≥1

    Day 1

Study Arms (1)

Indication for a genome-wide analysis in the proband

EXPERIMENTAL
Genetic: genome-wide analysesGenetic: Search for de novo mutations in paternal sperm samples

Interventions

genome-wide analyses will be done in patients and parents (father, mother)

Indication for a genome-wide analysis in the proband

Sperm analysis will be done in paternal samples

Indication for a genome-wide analysis in the proband

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Trio consisting of a child with a developmental disorder and both unaffected parents
  • Absence of etiology after clinical expertise and genetic testing
  • Indication of a genome-wide sequencing analysis
  • Child from spontaneous pregnancy without ovulation stimulation treatment
  • Availability of DNA blood samples
  • Affiliation to a social insurance
  • Patient or patient's legal representative who has read and understood the information letter and has signed the consent form

You may not qualify if:

  • Lack of indication for a genome-wide analysis in the proband
  • Etiology of the developmental disorder already identified
  • Proband born after In-Vitro Fertilization
  • Impossibility of non-invasive sperm collection from the father

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rouen University Hospital

Rouen, France

Location

Related Publications (2)

  • Lecoquierre F, Drouot N, Coutant S, Quenez O, Fourneaux S, Jumeau F, Rives N, Charbonnier F, Derambure C, Boland A, Olaso R, Meyer V, Deleuze JF, Goldenberg A, Guerrot AM, Charbonnier C, Nicolas G. Parental germline mosaicism in genome-wide phased de novo variants: Recurrence risk assessment and implications for precision genetic counselling. PLoS Genet. 2025 Mar 31;21(3):e1011651. doi: 10.1371/journal.pgen.1011651. eCollection 2025 Mar.

  • Lecoquierre F, Quenez O, Fourneaux S, Coutant S, Vezain M, Rolain M, Drouot N, Boland A, Olaso R, Meyer V, Deleuze JF, Dabbagh D, Gilles I, Gayet C, Saugier-Veber P, Goldenberg A, Guerrot AM, Nicolas G. High diagnostic potential of short and long read genome sequencing with transcriptome analysis in exome-negative developmental disorders. Hum Genet. 2023 Jun;142(6):773-783. doi: 10.1007/s00439-023-02553-1. Epub 2023 Apr 19.

MeSH Terms

Conditions

Developmental Disabilities

Condition Hierarchy (Ancestors)

Neurodevelopmental DisordersMental Disorders

Study Officials

  • François LECOQUIERRE, MD

    University Hospital, Rouen

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 21, 2020

First Posted

September 25, 2020

Study Start

February 24, 2021

Primary Completion

December 12, 2022

Study Completion

December 12, 2022

Last Updated

April 20, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations